Shorter overall survival among patients with monoclonal gammopathy of undetermined significance
1. Patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS) and followed for multiple decades showed shorter overall survival rates compared to matched controls.
2. Risk of progression to multiple myeloma or another blood cell disorder was associated with identified adverse risk factors.
Evidence Rating: 1 (Excellent)
Study Rundown: MGUS is a relatively common condition occurring in over 3% of persons age 50 or older which predisposes patients to increased risk of malignant plasma cell transformation. Prior studies have followed patients for less than 10 years, providing information regarding risks of malignant transformation. Data from longer follow-up is desired as the condition can be slowly progressive and have subtypes with different manifestations. This study follows a large group of MGUS patients for a median of 34.1 years. The primary endpoint of progression to multiple myeloma or plasma-cell or lymphoid disorders was increased compared to a control population, with risk of progression increasing as time with the condition increased. Adverse risk factors were identified which were associated with increased risk of progression. The IgM subtype of MGUS displayed an increased risk of progression compared to the non-IgM MGUS subtype. Overall survival was decreased in MGUS patients compared to matched controls.
This study provides improved natural history data on the progression of MGUS. Its strengths include large size and validation of adverse risk factors associated with disease progression, and a notable feature is the patient population was highly homogeneous.
In-Depth [prospective cohort]: This prospective cohort study followed 1384 patients for a total of 14 130 person-years from Minnesota diagnosed with MGUS at the Mayo Clinic between 1960 and 1994. Diagnostic criteria included a serum M protein level of 3 grams per deciliter or less and 10% or fewer plasma cells in bone marrow. Patients with light-chain MGUS were excluded. Follow-up consisted of Mayo medical records review and death certificate analysis. The primary endpoint was rate of progression to multiple myeloma or plasma-cell or lymphoid disorders in IgM (n = 210) and non-IgM (n = 1129) subtypes. Analysis of various prognostic factors associated with risk of progression was performed, as well as assessment of overall survival.
During the median of 34.1 years of follow-up 94% of patients passed away. Disease progression occurred in 11% of patients, at a risk 6.5 times higher than a matched cohort (95% confidence interval [CI], 5.5 to 7.7). Risk of disease progression was higher in the IgM (relative risk [RR], 10.8; 95% CI, 7.5 to 15.0) compared to non-IgM subtype (RR, 5.7; 95% CI, 4.7 to 6.9). Risk of progression was 10% at 10 years, 18% at 20 years, 28% at 30 years, 36% at 35 years, and 36% at 40 years. Initial concentration of serum M protein and serum free light-chain ratio were adverse risk factors associated with risk of progression. At 40 years, risk of death related to plasma- cell disorders was 11%. Compared to a matched cohort MGUS patients had a shorter median survival time (8.1 vs 12.4 years, p < 0.001).
©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Aspirin and Colorectal Cancer
- Study Reveals Scope of Genomic Variation Within Cancer Cell Lines
- IL-23 Drives Castration-Resistant Prostate Cancer
- Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer
- Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer
- FDA Grants Accelerated Approval to Nivolumab for Small Cell Lung Cancer
- Accelerated Intensity-Modulated Radiotherapy May Improve Outcomes in Localized Lung Cancer
- FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma
- COPD May Not Affect Survival in Patients With Small Cell Lung Cancer
- Prescription Drug Coverage in Medicare Part D Is Tied to a Survival Advantage in Myeloma